Business Wire

Yokogawa Survey Finds Two-Thirds of Process Industry Companies Are Anticipating Fully Autonomous Operations by 2030

Share

Yokogawa Electric Corporation (TOKYO: 6841) today revealed the results of a global end-user survey on the outlook for industrial autonomy*, which shows that 64% of respondents from companies in process industries are anticipating fully autonomous operations by 2030. The survey provides an in-depth view of future trends in automation and autonomy, business priorities, and technologies being deployed in key process industries including oil and gas, pharmaceuticals, chemicals, petrochemicals, and power generation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005058/en/

Technology investment over next 3 years (Graphic: Yokogawa Electric Corporation)

Technology investment over next 3 years (Graphic: Yokogawa Electric Corporation)

Key Insights

Companies are moving to fully autonomous operations by 2030, and will invest in technologies that aid decision-making

Sixty-four percent of respondents stated that they expect to reach autonomous operations in their primary operations by 2030. Eighty-nine percent said their companies currently have plans to increase the level of autonomy in their operations. Regarding their current status, 64% said that they are conducting or are piloting semi-autonomous or autonomous operations, while 67% expect significant automation of most decision-making processes in plant operations by 2023.

Cyber security (51%), cloud, analytics, and big data (47%), and artificial intelligence (42%) are three key areas in which companies are planning significant investment over the next three years. These will enable organizations to make better decisions across a greater span of control.

COVID-19 has put the brakes on economic growth in 2020 but will be a catalyst for the medium- to long-term growth of industrial autonomy.

COVID-19 has arguably presented a great impetus for industrial autonomy moving forward. A higher priority is now being placed on the ability to continue running operations without workers needing to be present. A majority of respondents are expecting to increase their investment in autonomous operations as a direct result of COVID-19.

Respondents were also asked to rank the top four applications in which they were directing investment as a result of the COVID-19 pandemic. Unsurprisingly, remote operations and remote servicing came out as two of the key applications for which priorities have increased, with a respective 36% and 30% of participants selecting them. The ability to conduct work without the need for workers to be present in a hazardous environment provides significant safety and cost benefits.

The survey also uncovered significant differences across industries in post-COVID-19 investment priorities. For example, compared with other industries, conventional power generation and chemical/petrochemical participants placed a greater focus on investments in worker safety.

Regional trends

The survey revealed regional differences in investment in new technologies and the push to industrial autonomy. Relative to other regions, Asia-Pacific is the most engaged in the shift to industrial autonomy. The survey found that the proportion of companies in Asia-Pacific that are prioritizing investment in autonomous systems for operations is 18% to 27% higher than other regions. This is a key statistic and shows that funding is being directed into autonomous operations in the region. Seventy-one percent of respondents in Asia-Pacific felt that they would attain fully autonomous operations in ten years' time, compared with just 58% in North America and 56% in Western Europe.

“From this research study, we have confirmed our perception that the shift from industrial automation to industrial autonomy, which we call IA2IA, is going to gain momentum over the next decade. As COVID-19 will accelerate this trend, and companies' interest in introducing related technologies continues to be strong, Yokogawa can support customers in strengthening their competitiveness step by step based upon our roadmap to autonomous operations,” said Tsuyoshi Abe, senior vice president and head of the Marketing Headquarters at Yokogawa.

Yokogawa believes the digital transformation of companies’ manufacturing and production operations will lead towards autonomous operations; the results of the survey demonstrate that companies are prioritizing and investing in the technologies of tomorrow in order to make this a reality.

The survey highlight report can be downloaded from the following website.

https://www.yokogawa.com/special/ia2ia/outlook/

* The “Global End-user Survey on the Outlook for Industrial Autonomy” was conducted on behalf of Yokogawa by research company Omdia among 504 decision-makers in process industry companies between June and July 2020.

About Yokogawa

Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business, the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 114 companies spanning 62 countries, generating US$3.7 billion in sales in FY2019. For more information, please visit www.yokogawa.com.

The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.

Contact information

Public Relations
Integrated Communications Center
Yokogawa Electric Corporation
Yokogawa-pr@cs.jp.yokogawa.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ESMO 2020: Cabometyx ® (cabozantinib) in Combination With Opdivo ® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 18:30:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 12:55:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 12:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline ® Autogel ® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 07:00:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel®(lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatmen

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom